Somatomedin-C mediates growth hormone negative feedback by effects on both the hypothalamus and the pituitary.
about
Human conditions of insulin-like growth factor-I (IGF-I) deficiencyTargeting the insulin-like growth factor pathway in hepatocellular carcinomaInsulin-like growth factor-1 deficiency and metabolic syndromeType I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinomaCircumventricular organs: definition and role in the regulation of endocrine and autonomic functionMeasurement of growth hormone-releasing hormone and somatostatin in hypothalamic-portal plasma of unanesthetized sheep. Spontaneous secretion and response to insulin-induced hypoglycemiaEstradiol and progesterone regulate the expression of insulin-like growth factor-I receptor and insulin-like growth factor binding protein-2 in the hypothalamus of adult female ratsIntracerebroventricular administration of the rat growth hormone (GH) receptor antagonist G118R stimulates GH secretion: evidence for the existence of short loop negative feedback of GH.A low dose euglycemic infusion of recombinant human insulin-like growth factor I rapidly suppresses fasting-enhanced pulsatile growth hormone secretion in humans.Fasting enhances growth hormone secretion and amplifies the complex rhythms of growth hormone secretion in man.IGF-1 modulates gene expression of proteins involved in inflammation, cytoskeleton, and liver architecture.Effect of acute elevation of IGF-I on circulating GH, TSH, insulin, IGF-II and IGFBP-3 levels in non-endocrine short stature (NESS).The use of immunoliposome for nutrient target regulation (a review).Insulin-like growth factors-I and -II differentially regulate endogenous acetylcholine release from the rat hippocampal formationSafety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial.Effects of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects.Targeted deletion of somatotroph insulin-like growth factor-I signaling in a cell-specific knockout mouse modelEndocrine-disrupting chemicals: prepubertal exposures and effects on sexual maturation and thyroid function in the male rat. A focus on the EDSTAC recommendations. Endocrine Disrupter Screening and Testing Advisory Committee.Chronic growth hormone (GH) hypersecretion induces reciprocal and reversible changes in mRNA levels from hypothalamic GH-releasing hormone and somatostatin neurons in the rat.Insulin-like growth factor I stimulates lipid oxidation, reduces protein oxidation, and enhances insulin sensitivity in humansInsulin-like growth factor-I for the treatment of type 1 diabetes.Comparison of the effects of growth hormone and insulin-like growth factor I on substrate oxidation and on insulin sensitivity in growth hormone-deficient humans.Short stature--physiology and pathologyAcromegaly update--etiology, diagnosis and management.Negative feedback regulation of pulsatile growth hormone secretion by insulin-like growth factor I. Involvement of hypothalamic somatostatin.Growth hormone potentiates 17β-estradiol-dependent breast cancer cell proliferation independently of IGF-I receptor signaling.Insulin regulation of rat growth hormone gene transcription.Insulinlike growth factor I regulation of growth hormone gene transcription in primary rat pituitary cellsInsulin suppresses growth hormone secretion by rat pituitary cellsThe therapeutic potential of recombinant human insulin-like growth factor-I.Effect of obesity on endogenous secretion of growth hormone in Turner's syndrome.Thyroid hormones and growth hormone secretion.Molecular pathogenesis and targeted therapeutics in Ewing sarcoma/primitive neuroectodermal tumours.IGF-1 in the brain as a regulator of reproductive neuroendocrine function.Class II G protein-coupled receptors and their ligands in neuronal function and protectionLong-term depression of glutamate-induced gamma-aminobutyric acid release in cerebellum by insulin-like growth factor IRegulation of muscle mass by growth hormone and IGF-I.GH/IGF-I axis in anorexia nervosa.A Human Variant of Glucose-Regulated Protein 94 That Inefficiently Supports IGF Production.In vitro impact of pegvisomant on growth hormone-secreting pituitary adenoma cells.
P2860
Q26822806-B6DA8C60-DC1B-45C6-944B-25934F564323Q27006846-C0946E59-0F68-4AF7-8D03-D8F80DDCB235Q28072410-E191468A-77AC-4AB7-9AF7-959700FF8D29Q28080514-347232D2-8673-4A11-9C1C-5B7D34967AF5Q28145397-2C5303A5-F1C8-4E09-A52C-30B1680C1094Q28257465-46E31BEF-EFA6-4AC3-AFC7-6CC60C506389Q28571477-565A0564-34CB-4DC3-9207-D21283E7CEEFQ30306529-238059BE-3696-4557-8849-4ACCCE0511B4Q30449290-5B3731AF-858D-41D5-8142-B74746E4DBA2Q30449349-11732E4B-498C-482C-BE79-84B93B36B05BQ30846570-9590926C-9274-4E4F-8BEB-491B2604C9CEQ32066576-6C279342-38F5-4C31-ABBA-685D7C0178D9Q33263078-90F82969-473E-466E-A142-0C27E814A9CCQ33744136-3F4F9F9E-9AA2-4148-A442-CDA7F12189C4Q33803331-7215B6A1-FBDD-49FF-82F6-EC92EF03DE1FQ33851134-C31ACD0C-A58A-4440-9EC3-018FBA3F03ABQ33853035-208037BE-16F2-4485-A15D-A12D42F5093BQ33888391-6C3FDF94-0B65-449C-84A4-FF594D864E5BQ33897071-944BEE71-B660-4324-8A17-476FF49996FBQ33907536-BDFD41C5-A86E-4626-A740-4528868E27BEQ34166740-85EB6739-78D3-4760-A553-47D2A7B5ED23Q34184378-989B89A2-86AB-447C-9CB6-9200020B06DEQ34193806-70483CF4-6E6A-416A-9570-0601FE34EC28Q34195293-120FCCD4-0D1F-46A8-8647-75D56ED6A317Q34234505-AB94D0D5-F7E3-443D-95B5-99A171CA24F2Q34352011-ACFE73FC-56B6-485E-B62F-B89F970AB5E0Q34542635-88A19474-7AA5-4AF4-BB69-B40EE77F94D6Q34559166-B19DE3DD-C2C8-4B9C-A4EC-0718EC681C20Q34610080-A9967C93-F433-40E1-B184-AF79005DE68BQ35479134-749D9273-4F85-43E0-947C-FE64D92A4F82Q35627599-D5F380B0-24C1-4A24-B5EA-0C89DBF0AA21Q35763492-66C0920A-59C5-40D4-92B8-F59DCE912D92Q35957998-7F51AA8E-7665-4A36-BAE3-8B7EE2A709EBQ36108290-10155C0F-3DFD-4437-A651-28CCEDCB688FQ36211439-930DA43D-DAB3-4938-993D-AA50D9D5710FQ36466140-A302AF5A-132E-4B9C-A4B8-8895141E9B1BQ36736100-D59934B5-091C-43FD-B05B-413D9A5C9601Q36888642-FDB623AF-B09D-46CD-A292-6E33B46F8CA0Q36911625-2A79F26C-FCA0-48EA-8664-03E29D0093AAQ37340504-4A6E2FEF-4CE7-42A9-BC0E-6E9BD8F2D820
P2860
Somatomedin-C mediates growth hormone negative feedback by effects on both the hypothalamus and the pituitary.
description
1981 nî lūn-bûn
@nan
1981年の論文
@ja
1981年論文
@yue
1981年論文
@zh-hant
1981年論文
@zh-hk
1981年論文
@zh-mo
1981年論文
@zh-tw
1981年论文
@wuu
1981年论文
@zh
1981年论文
@zh-cn
name
Somatomedin-C mediates growth ...... ypothalamus and the pituitary.
@en
Somatomedin-C mediates growth ...... ypothalamus and the pituitary.
@nl
type
label
Somatomedin-C mediates growth ...... ypothalamus and the pituitary.
@en
Somatomedin-C mediates growth ...... ypothalamus and the pituitary.
@nl
prefLabel
Somatomedin-C mediates growth ...... ypothalamus and the pituitary.
@en
Somatomedin-C mediates growth ...... ypothalamus and the pituitary.
@nl
P2093
P356
P1433
P1476
Somatomedin-C mediates growth ...... ypothalamus and the pituitary.
@en
P2093
P304
P356
10.1126/SCIENCE.6262917
P407
P577
1981-06-01T00:00:00Z